Management Committee

Dan Adams,
JD 
Chairman,
EpiVax Oncology  
Headshot.jpg
Anne (Annie)
De Groot, MD 
Co-Founder/CEO/CSO, EpiVax  
Bill Martin, 
BA
Co-Founder/CTO/COO, EpiVax   
Bill Martin.jpg
image-2018-11-13-3.png
Bill Martin.jpg
Bill Martin, 
BA
Co-Founder/CTO/COO, EpiVax   

Senior Technical Team

gary-d-steinberg-square.jpg
Gary Steinberg, MD
Consulting Chief Medical Officer

Gary Steinberg, MD, specializes in urologic oncology. He has been instrumental in developing innovative surgical procedures for patients with bladder cancers. In addition, Dr. Steinberg’s research includes developing new treatments for urologic cancers, especially bladder cancer. He has performed over 2500 radical cystectomies and is a national leader in continent urinary tract reconstruction. He has been a national principal investigator, scientific advisor and protocol development advisor for multiple innovative clinical trials and translational research studies utilizing novel agents including oncolytic vaccines and immunotherapeutic agents. He has been a key advisor in clinical trial design, protocol development, study completion and analysis for patients with high risk non-muscle invasive bladder cancer.

Read Gary's full bio here...

Michael Princiotta, PhD
Chief Scientific Officer

Michael Princiotta brings over 20 years experience in T cell immunology and antigen processing and presentation to Epivax Oncology. Most recently, he was Vice President of Research at Advaxis Immunotherapies where, as head of research, he oversaw the development of a personalized cancer vaccine from conception to Phase I clinical trial. Michael holds a Master of Science in Microbiology and Molecular Biology from the University of Central Florida and a PhD in Microbiology and Immunology from the University of Colorado Health Science Center in Denver Colorado. 

Read Michael's full bio here. . .

M7_06364_600x600.jpg
Guilhem Richard, PhD
Lead Computational Immunologist 

Guilhem Richard brings immunoinformatics expertise to the EpiVax Oncology team. He has been a Computational Immunologist for over 4 years at EpiVax, focusing on refining its immuno-oncology platform. He holds a Master of Engineering in Bioinformatics and Modeling from the National Institute of Applied Science (INSA) of Lyon, France, and a Ph.D. in Bioinformatics from Boston University.

Read Guilhem's full bio here. . .

Board of Directors

Headshot.jpg
Daniel Adams, JD
Chairman 

Daniel Adams is the Executive Chairman and Co‐Founder of NextWaveBio, a next‐generation biotechnology enterprise developing safer, more affordable pharmaceuticals. Mr. Adams served as CEO then as the Executive Chairman of Protein Sciences Corporation, a leader in developing and manufacturing vaccines, therapeutics and diagnostics, including Flublok®, a patented, first in class recombinant influenza vaccine, that received licensure from FDA in 2013. The Company was acquired by Sanofi for approximately $750 million. Previously Dan founded and managed several biotechnology companies including Biogen that achieved a combined value of well in excess of $60 billion. 

Read Dan's full bio here. . .

Rick Lipkin, 
MBA
 
Managing Director, Easton Capital 
Gad Berdugo, MSc. Eng., MBA
Rick Lipkin.png
Anne (Annie)
De Groot, MD
 
Co-Founder/CEO/CSO, EpiVax  
image-2018-11-13-3.png
Bill Martin, 
BA
Co-Founder/CTO/COO, EpiVax   
Bill Martin.jpg

PROVIDENCE

188 Valley Street

Suite 424

Providence, RI 02909

+1(401) 272.2123

© Copyright Epivax Oncology 2020